Miriam Mwachinga: Let’s Focus More on Rare Diseases and Their Impact on Quality of Life
Miriam Mwachinga, General Practitioner, Internal Medicine, Medical Affairs at Healthcare Industry, Pharmaceutical Ind, shared on LinkedIn:
”One of my college professors once made a comment that has stayed with me over the years.
Diseases that affect 1 in a million often seem insignificant, but the impact on your quality of life if you are that 1 person in a million is huge.
Rare diseases tend to be overlooked because the cost: benefit ratio doesn’t make economic sense when it comes to drug development, but that doesn’t make them any less significant.
Hemophilia A is the most common genetic X-linked disease, but still far behind when it comes to clinical research.
With Rare Disease Day coming up later this month, let’s all focus a bit more on rare diseases.”
Stay updated with Hemostasis Today.
-
Apr 1, 2026, 18:46Fritz Torto: Why Every Survivor Has a Duty to Build a Stronger Future for Others
-
Apr 1, 2026, 17:47Akshaya Sharon: Qfitlia as a Shift in Treatment Strategy for Hemophilia A and B
-
Apr 1, 2026, 17:21Antonio Pineda Guerrero: Elevated Lp(a) Raises VTE Risk But Only in the Right Hormonal Context
-
Apr 1, 2026, 17:19Shaik Nayeem Uddin: Clopidogrel and Omeprazole Combination Can Quietly Reduce A Life-Saving Effect
-
Apr 1, 2026, 17:18John Abraham: Breaking the ‘Bleeding Disorder’ Myth About Cirrhosis and Coagulation
-
Apr 1, 2026, 17:17Heghine Khachatryan: Linking Coagulation, Inflammation, and Neurodegeneration In Neuro-Hemostasis Axis
-
Apr 1, 2026, 17:15Chokri Ben Lamine: Differentiating Reactive from Clonal Causes in Adult Neutrophilia
-
Apr 1, 2026, 16:05Gregory Piazza: Discussing the 2026 AHA/ACC Guidelines for Acute PE at ACC.26
-
Apr 1, 2026, 15:31Simon Senanu: A Stepwise Laboratory Approach for aPTT Prolongation